Autologous cord blood in children with cerebral palsy: a review
AbstractThe aim of this narrative review is to report on the current knowledge regarding the clinical use of umbilical cord blood (CB) based on articles from PubMed and clinical trials registered on ClinicalTrials.gov. An increasing amount of evidence suggests that CB may be used for both early diagnostics and treatment of cerebral palsy. The acidity of CB and its biochemical parameters, including dozens of cytokines, growth factors, and other metabolites (such as amino acids, acylcarnitines, phosphatidylcholines, succinate, glycerol, 3-hydroxybutyrate, and O-phosphocholine) are predictors of future neurodevelopment. In addition, several clinical studies confirmed the safety and efficacy of CB administration in both autologous and allogeneic models, including a meta-analysis of five clinical trials involving a total of 328 participants. Currently, nine clinical trials assessing the use of autologous umbilical CB in children diagnosed with hypoxic-ischemic encephalopathy or cerebral palsy are in progress. The total population assessed in these trials exceeds 2500 patients.
Share & Cite This Article
Boruczkowski, D.; Pujal, J.-M.; Zdolińska-Malinowska, I. Autologous cord blood in children with cerebral palsy: a review. Int. J. Mol. Sci. 2019, 20, 2433.
Boruczkowski D, Pujal J-M, Zdolińska-Malinowska I. Autologous cord blood in children with cerebral palsy: a review. International Journal of Molecular Sciences. 2019; 20(10):2433.Chicago/Turabian Style
Boruczkowski, Dariusz; Pujal, Josep-Maria; Zdolińska-Malinowska, Izabela. 2019. "Autologous cord blood in children with cerebral palsy: a review." Int. J. Mol. Sci. 20, no. 10: 2433.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.